Gaudium IVF and Women Health Ltd

Gaudium IVF and Women Health Limited has announced that its Board of Directors will convene on November 12, 2026. The primary agenda items include the consideration and approval of the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. The meeting will also involve taking on record the Auditor’s Limited Review Report. The company will submit the outcome of the board meeting and the auditor's report as per SEBI Listing Regulations. Additionally, the trading window for designated persons will remain closed until 48 hours after the declaration of these results, as per the Insider Trading Regulations.

Gaudium IVF and Women Health Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal codes. The window will remain shut from October 1, 2026, until 48 hours after the announcement of the unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2026. The specific date for the board meeting to approve these results will be communicated separately.

Gaudium IVF and Women Health Ltd has announced the commencement of commercial operations at its new IVF Centre/Hub in Gurgaon, Haryana, effective September 24, 2026. This expansion aligns with the company's Initial Public Offer objectives. The new facility offers comprehensive fertility and reproductive healthcare services, featuring the proprietary Gaudium Signature Lab with advanced embryology and AI-powered technologies to ensure high standards of precision and clinical excellence.

Gaudium IVF and Women Health Ltd has dispatched physical letters to shareholders whose email addresses are not registered, providing the weblink and navigation path to access the Annual Report for the Financial Year 2025-26. This action is in compliance with Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also informed that its 11th Annual General Meeting is scheduled for September 28, 2026. Shareholders are encouraged to register their email IDs for electronic communication and consider dematerializing physical holdings. The Annual Report and AGM Notice are also available on the NSE and Bigshare Services websites. Physical copies can be requested via email.

Gaudium IVF and Women Health Ltd has filed its Annual Report for the Financial Year 2025-26, coinciding with the notice for its 11th Annual General Meeting (AGM) scheduled for September 28, 2026. The report highlights the company's journey from a founder-led enterprise to an institution-led platform, emphasizing its growth through a hub-and-spoke model with seven hubs and 28 spokes across India. Key achievements include the integration of AI-led embryology tools and its listing on NSE and BSE on February 27, 2026. The company aims to expand access to fertility care in Tier 1 and Tier 2 cities, building on its foundation of clinical excellence and institutional capability.

Gaudium IVF and Women Health Ltd has issued a notice for its 11th Annual General Meeting (AGM) scheduled for Monday, September 28, 2026, at 02:00 P.M. (IST). The meeting will be conducted virtually through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026, the re-appointment of Mr. Vishad Khanna as a Director retiring by rotation, and the approval of revised remuneration for Dr. Peeyush Khanna, a Whole-Time Director. The notice, along with the Annual Report for FY 2025-26, will be sent via email to registered members by August 28, 2026.

Gaudium IVF and Women Health Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report, issued by Infomerics Valuation and Rating Limited, confirms that there have been no deviations from the objects for which the Initial Public Offer (IPO) proceeds of ₹90.00 crore were earmarked. The monitoring agency reviewed bank statements, utilization certificates, board resolutions, and invoices to verify the utilization of funds. The company has also uploaded this report on its website.

Gaudium IVF and Women Health Ltd reported unaudited financial results for Q1FY27, with Revenue from Operations reaching ₹19.4 Cr, a 9.13% year-on-year increase. This growth was driven by higher patient volumes and international contributions. However, EBITDA saw a significant decline of 52.96% to ₹2.4 Cr, and Profit After Tax (PAT) fell by 42.27% to ₹1.8 Cr. The company attributed the profitability dip to investments in expansion, including pre-operational costs for new hubs and hiring clinical talent. Key operational highlights include the commencement of operations at a new IVF Hub in South Extension, New Delhi, and board approval for 'Gaudium Women Hospital, Lucknow' with an estimated project cost of ₹15 crore. The company maintained a strong clinical pregnancy success rate of 62% on the first IVF attempt.

Gaudium IVF and Women Health Ltd announced the appointment of M/s. Suresh Nainwal & Company as its Secretarial Auditor for a term of five consecutive years, commencing from FY 2026-27 to FY 2030-31. This appointment is subject to the approval of the company's shareholders at the upcoming Annual General Meeting. The Board of Directors approved this appointment based on the recommendation of the Audit Committee during their meeting held on August 13, 2026. The company also approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and the re-appointment of Ram Rattan & Associates as Internal Auditor for FY 2026-27.

Gaudium IVF and Women Health Ltd announced the appointment of Ram Rattan & Associates as the Internal Auditor for the Financial Year 2026-27. This decision was made during the Board Meeting held on August 13, 2026. The company also approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and the appointment of M/s. Suresh Nainwal & Company as Secretarial Auditor for five years starting FY 2026-27. The 11th AGM is scheduled for September 28, 2026.